Vaccine trial in Africa to take aim at dreaded hookworm
The first African clinical trial of an experimental vaccine against hookworm is planned for next year. Hookworm infestations are a serious problem for 600 million of the world’s poor.
The New York Times
The first African clinical trial of an experimental vaccine against hookworm is planned for next year.
While rarely fatal, hookworm infestations are a serious problem for 600 million of the world’s poor, especially for children going barefoot. By constantly draining their victims’ blood, the worms cause anemia, stunted growth and learning problems, and leave children too weak to go to school. When they infest pregnant women, both mother and fetus are weakened.
The worms enter through the feet and ride the bloodstream to exit in the lungs, where they are coughed up and then swallowed. Once in the intestines, they attach and suck blood. They grow to half an inch long.
Dr. Peter Hotez, director of the Sabin Vaccine Institute, explained that the vaccine creates antibodies not against the parasite itself, but against two enzymes found in the worm’s own gut — one that detoxifies the iron in its blood diet, and another that digests blood proteins. Without those enzymes the worm slowly dies.
The trial will start on a few adults in Gabon, and children will eventually be enrolled. Even if all goes well, the trial could take at least five years. But Hotez noted that he began work on the vaccine as a graduate student at Rockefeller University 30 years ago, “and I’ve been working on it my whole life.”